Exact Sciences is a biotechnology company focused on the development and commercialization of innovative cancer screening and diagnostic solutions
With a primary emphasis on early detection, the company aims to improve patient outcomes through advanced molecular tests, including non-invasive tests that help identify colorectal cancer and other cancers at an early stage. Exact Sciences combines sophisticated technology, rigorous scientific research, and a commitment to patient care to provide healthcare providers and patients with critical information that can lead to timely interventions and better health management.
Top performers last week: RIVN, RKLB, SRPT, EXAS, ESTC, ULTA, MRNA, RL, CPRT, SNAP. Any in your portfolio? Citigroup raises price target on ULTA and SNAP.
Centers for Medicare & Medicaid Services finalizes 2025 pricing for Exact Sciences' Cologuard Plus, raising Medicare reimbursement by 16% and boosting growth projections for next year.
U.S. stocks could open on a sluggish note on Tuesday after ending in green on Monday as President-elect Donald Trump threatened to hit two of U.S.'s largest trading partners - Canada and Mexico - with tariffs.
Exact Sciences Q3 EPS loss of $0.21 fell short of analyst expectations. 2024 revenue guidance lowered amid screening segment hurdles, growth plans set for 2025.
Exact Sciences' Cologuard Plus test, now FDA-approved, offers a non-invasive screening option for adults 45+ at average risk for colorectal cancer. The test outperformed fecal immunochemical tests in detecting CRC and precancerous lesions.
